Your browser doesn't support javascript.
loading
Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease.
Vrba, Lukas; Futscher, Bernard W; Oshiro, Marc; Watts, George S; Menashi, Emmanuel; Hu, Charles; Hammad, Hytham; Pennington, Daniel R; Golconda, Umamaheshwari; Gavini, Hemanth; Roe, Denise J; Shroff, Rachna T; Nelson, Mark A.
Afiliación
  • Vrba L; The University of Arizona Cancer Center, Tucson, AZ, USA.
  • Futscher BW; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
  • Oshiro M; The University of Arizona Cancer Center, Tucson, AZ, USA.
  • Watts GS; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
  • Menashi E; Precision Epigenomics Inc, Tucson, AZ, USA.
  • Hu C; The University of Arizona Cancer Center, Tucson, AZ, USA.
  • Hammad H; The University of Arizona Cancer Center, Tucson, AZ, USA.
  • Pennington DR; Department of Medical Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
  • Golconda U; Honor Health Hospital, Scottsdale, AZ, USA.
  • Gavini H; Dignity Health Chandler Regional Medical Center, Chandler, AZ, USA.
  • Roe DJ; The University of Arizona Cancer Center, Tucson, AZ, USA.
  • Shroff RT; Division of Hematology/Oncology, Department of Medicine, University of Arizona Caner Center, Tucson, AZ, USA.
  • Nelson MA; The University of Arizona Cancer Center, Tucson, AZ, USA.
Clin Epigenetics ; 14(1): 28, 2022 02 22.
Article en En | MEDLINE | ID: mdl-35193708
ABSTRACT
We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Pancreáticas / Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Epigenetics Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Pancreáticas / Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Epigenetics Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos